139 related articles for article (PubMed ID: 8059616)
1. Differential reduction in the volume of leiomyoma and uterus during buserelin treatment.
Puzigaća Z; Prelević GM; Sretenović Z
Gynecol Endocrinol; 1994 Mar; 8(1):39-43. PubMed ID: 8059616
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous injection or infusion of gonadotropin releasing-hormone agonist buserelin in the treatment of enlarged uteri harboring leiomyomata.
Franssen AM; Willemsen WN; Corbey RS; Doesburg WH; van 't Veen AJ; Rolland R
Eur J Obstet Gynecol Reprod Biol; 1991 Jul; 40(3):221-8. PubMed ID: 1908799
[TBL] [Abstract][Full Text] [Related]
3. Treatment of uterine leiomyomas in perimenopausal women with gonadotropin-releasing hormone agonists.
Nakamura Y; Yoshimura Y
Clin Obstet Gynecol; 1993 Sep; 36(3):660-7. PubMed ID: 8403612
[No Abstract] [Full Text] [Related]
4. Treatment of uterine leiomyomata with a luteinizing hormone-releasing hormone agonist: the possibility of nonsurgical management in selected perimenopausal women.
Nakamura Y; Yoshimura Y; Yamada H; Ubukata Y; Ando M; Suzuki M
Fertil Steril; 1991 May; 55(5):900-5. PubMed ID: 1902420
[TBL] [Abstract][Full Text] [Related]
5. [Preoperative reduction of uterine leiomyoma by the GnRH-analog goserelin (zoladex)].
Hackenberg R; Gesenhues T; Deichert U; Duda V; Sturm G; Schulz KD
Geburtshilfe Frauenheilkd; 1990 Feb; 50(2):136-9. PubMed ID: 2138580
[TBL] [Abstract][Full Text] [Related]
6. Luteinizing hormone-releasing hormone agonist and uterine leiomyoma: a pilot study.
Maheux R; Guilloteau C; Lemay A; Bastide A; Fazekas AT
Am J Obstet Gynecol; 1985 Aug; 152(8):1034-8. PubMed ID: 3927734
[TBL] [Abstract][Full Text] [Related]
7. Uterine leiomyoma and LHRH agonist treatment. A preliminary report.
Rolland R; Franssen AM; Willemsen WN; Corbey RS
Prog Clin Biol Res; 1986; 225():313-20. PubMed ID: 3097670
[No Abstract] [Full Text] [Related]
8. Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin.
Matta WH; Shaw RW; Nye M
Br J Obstet Gynaecol; 1989 Feb; 96(2):200-6. PubMed ID: 2495020
[TBL] [Abstract][Full Text] [Related]
9. Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography.
Donnez J; Schrurs B; Gillerot S; Sandow J; Clerckx F
Fertil Steril; 1989 Jun; 51(6):947-50. PubMed ID: 2498131
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of leiomyomas with luteinizing hormone-releasing hormone agonist].
Nakamura Y; Yoshimura Y; Yamada H; Maruyama K; Nanno T; Ubukata Y; Ando M; Takahashi K; Suzuki M
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Dec; 42(12):1620-6. PubMed ID: 2126024
[TBL] [Abstract][Full Text] [Related]
11. [Shrinkage of uterine leiomyomas after intranasal administration of a LHRH agonist].
Uemura T; Kimura A; Shirasu K; Minaguchi H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Mar; 41(3):365-8. PubMed ID: 2499643
[No Abstract] [Full Text] [Related]
12. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis.
Friedman AJ; Lobel SM; Rein MS; Barbieri RL
Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1114-9. PubMed ID: 2145765
[TBL] [Abstract][Full Text] [Related]
13. A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis.
Takeuchi H; Kobori H; Kikuchi I; Sato Y; Mitsuhashi N
J Obstet Gynaecol Res; 2000 Oct; 26(5):325-31. PubMed ID: 11147718
[TBL] [Abstract][Full Text] [Related]
14. Uterine leiomyoma: treatment with LHRH agonist.
Maheux R; Lemay A
Prog Clin Biol Res; 1986; 225():297-311. PubMed ID: 3097669
[No Abstract] [Full Text] [Related]
15. Dose-related inhibition of acute luteinizing hormone response during luteinizing hormone-releasing hormone agonist treatment for uterine leiomyoma.
Maheux R; Lemay A; Turcot-Lemay L
Am J Obstet Gynecol; 1988 Feb; 158(2):361-4. PubMed ID: 3124621
[TBL] [Abstract][Full Text] [Related]
16. Luteinizing hormone-releasing hormone analog therapy of uterine fibroid: analysis of results obtained with buserelin administered intranasally and goserelin administered subcutaneously as a monthly depot.
Costantini S; Anserini P; Valenzano M; Remorgida V; Venturini PL; De Cecco L
Eur J Obstet Gynecol Reprod Biol; 1990 Oct; 37(1):63-9. PubMed ID: 2142921
[TBL] [Abstract][Full Text] [Related]
17. Endocrinological and histological changes after treatment of uterine leiomyomas with danazol or buserelin.
Ueki M; Okamoto Y; Tsurunaga T; Seiki Y; Ueda M; Sugimoto O
J Obstet Gynaecol (Tokyo 1995); 1995 Feb; 21(1):1-7. PubMed ID: 8591104
[TBL] [Abstract][Full Text] [Related]
18. Regression of leiomyomata uteri following hypoestrogenism induced by repetitive luteinizing hormone-releasing hormone agonist treatment: preliminary report.
Maheux R; Guilloteau C; Lemay A; Bastide A; Fazekas AT
Fertil Steril; 1984 Oct; 42(4):644-6. PubMed ID: 6436065
[No Abstract] [Full Text] [Related]
19. [Medical treatment of uterine leiomyomatosis with an agonist of pituitary gonadotropins (GnRH). Presentation of a case].
Bustos HH; López Garcia R; Sánchez V; Contreras J; Ayala Ruiz A
Ginecol Obstet Mex; 1990 Sep; 58():260-4. PubMed ID: 2125961
[TBL] [Abstract][Full Text] [Related]
20. Treatment of estrogen-dependent gynecological disorders with the gonadotropin releasing hormone agonist buserelin.
Biberoglu K; Gursoy R; Yildiz A
Gynecol Endocrinol; 1991 Jun; 5(2):109-22. PubMed ID: 1833953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
